LEADER 01065nam0-22003371i-450- 001 990007833030403321 005 20080115104306.0 010 $a3-88073-587-5 035 $a000783303 035 $aFED01000783303 035 $a(Aleph)000783303FED01 035 $a000783303 100 $a20031022d2001----km-y0itay50------ba 101 0 $ager 102 $aDE 105 $ay---a---001yy 200 1 $aDignitas und auctoritas$eder römische Senat und Augustus. Prosopographische Überlegungen zur Karriere der Konsuln und Statthalter 30 v. Chr. bis 14 n. Chr.$fJens Nitschke 210 $aMünchen$cTuduv$d2001 215 $a217 p.$d21 cm 225 1 $aQuellen und Forschungen zur antiken Welt$v39 610 0 $aRoma antica$aSenato$aEtà augustea 676 $a937.06$v20 676 $a320.937$v20 700 1$aNitschke,$bJens$0280479 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007833030403321 952 $aDDR-XX Dc I 150$b07495 ddr$fDDR$m21-4435 959 $aDDR 996 $aDignitas und auctoritas$9663837 997 $aUNINA LEADER 00962nas 2200349- 450 001 9910502916803321 005 20150924095924.0 035 $a(CKB)5300000000020165 035 $a(CONSER)--2015218866 035 $a(OCoLC)19568606 035 $a(EXLCZ)995300000000020165 100 $a20150924b18841888 k-- a 101 0 $aeng 135 $aur|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe Palatka daily news 210 1$aPalatka, Florida :$cSpeer & Harrison 215 $a1 online resource 311 $a2381-0610 517 1 $aDaily news 607 $aPalatka (Fla.)$vNewspapers 607 $aPutnam County (Fla.)$vNewspapers 607 $aFlorida$zPalatka$2fast 607 $aFlorida$zPutnam County$2fast 608 $aNewspapers.$2fast 676 $a071 906 $aNEWSPAPER 912 $a9910502916803321 996 $aThe Palatka daily news$91890814 997 $aUNINA LEADER 03139nam 2200361z- 450 001 9910136403703321 005 20210211 035 $a(CKB)3710000000612060 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54550 035 $a(oapen)doab54550 035 $a(EXLCZ)993710000000612060 100 $a20202102d2014 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNew anti-infective strategies for treatment of tularemia 210 $cFrontiers Media SA$d2014 215 $a1 online resource (78 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-339-X 330 $aFrancisella tularensis, the causative agent of tularemia, is a paradigm among human pathogens. This Gram-negative bacterium has an intracellular lifestyle, which probably reflects an adaptation to its natural animal and protozoa reservoirs. This is one of the most infectious agents in humans and animals; only a few bacteria are needed to induce a severe infection in both types of hosts. The clinical presentation and severity of human tularemia varies according to the portal of entry of bacteria, the bacterial inoculum, the virulence of the infecting strain, and the immune response of the host. Although most infections occur after direct inoculation of bacteria through the skin (through skin wounds or bites of arthropods), pneumonia due to inhalation of infected aerosols is the most feared of the clinical forms of the disease, particularly in the context of biological threat. Two subspecies are responsible for tularemia (subsp. tularensis and subsp. holarctica), and several clades have been described for each, which might be associated with changes in disease severity in humans. Tularemia is also more severe in people with an impaired immune response. No safe vaccine is currently available for prophylaxis of tularemia in humans. On the other hand, control of proliferation of F. tularensis in wildlife is not feasible. Thus, only the anti-infective agents are used for treatment and prophylaxis of human tularemia. The standard options include aminoglycosides (gentamicin), tetracyclines (eg, doxycycline) and fluoroquinolones (eg, ciprofloxacin). The selection of acquired resistance to these antibiotics in F. tularensis, especially in the context of a biological threat, may quickly limit the therapeutic options. New prophylactic and therapeutic alternatives must be developed rapidly. The present Research Topic focuses on potential new strategies for treatment of tularemia, including the development and evaluation of new compounds having proper antibacterial activity, reducing the virulence of F. tularensis or enhancing the immune host response. 610 $aantiinfective agents 610 $aFrancisella tularensis 610 $aimmunomodulators 610 $aTularemia 610 $aVirulence 700 $aMax Maurin$4auth$01287805 906 $aBOOK 912 $a9910136403703321 996 $aNew anti-infective strategies for treatment of tularemia$93020428 997 $aUNINA